Epigral Q2 FY27 results: Total Revenue Rs 752.00 cr, PAT Rs 64.00 cr
Epigral Limited reported Total Revenue of Rs 752.00 cr and PAT of Rs 64.00 cr in Q2FY27, up from Rs 589.00 cr and Rs 51.00 cr in Q2FY26.
Key takeaways
- Total Revenue Rs 752.00 cr in Q2FY27 vs Rs 589.00 cr in Q2FY26
- PAT Rs 64.00 cr in Q2FY27 vs Rs 51.00 cr in Q2FY26
- EBITDA Rs 136.00 cr in Q2FY27 vs Rs 132.00 cr in Q2FY26
- Gross Margin 32% in Q2FY27 vs 37% in Q2FY26
- EPS 14.9 in Q2FY27 vs 11.9 in Q2FY26
Q2FY27 · standalone
| Metric | Sep 2026 | Sep 2025 | Change |
|---|---|---|---|
| Revenue | Rs 752.00 cr | Rs 589.00 cr | +27.7% |
| PAT | Rs 64.00 cr | Rs 51.00 cr | +25.5% |
As reported in the filing. Figures are transcribed, not computed.
What the numbers show
- Net margin was 8.51% of revenue, against 8.66% a year earlier.
Key Q2FY27 numbers (vs Q2FY26)
From the Income Statement table in the statement of financial results for Q2FY27 (labelled "Income Statement"):
- Total Revenue: Rs 752.00 cr (Q2FY26: Rs 589.00 cr)
- Gross Profit: Rs 236.00 cr (Q2FY26: Rs 220.00 cr)
- Gross Margin (%): 32% (Q2FY26: 37%)
- EBITDA: Rs 136.00 cr (Q2FY26: Rs 132.00 cr)
- EBITDA Margin (%): 18% (Q2FY26: 23%)
- Depreciation: Rs 44.00 cr (Q2FY26: Rs 42.00 cr)
- Finance Cost: Rs 11.00 cr (Q2FY26: Rs 22.00 cr)
- PBT: Rs 87.00 cr (Q2FY26: Rs 70.00 cr)
- PAT: Rs 64.00 cr (Q2FY26: Rs 51.00 cr)
- PAT Margin (%): 9% (Q2FY26: 9%)
- EPS (Rs): 14.9 (Q2FY26: 11.9)
For context, the same Income Statement table also provides half-year figures:
- H1FY27 Total Revenue: Rs 1,461.00 cr (H1FY26: Rs 1,204.00 cr)
- H1FY27 Gross Profit: Rs 513.00 cr (H1FY26: Rs 472.00 cr)
- H1FY27 Gross Margin (%): 35% (H1FY26: 40%)
- H1FY27 EBITDA: Rs 315.00 cr (H1FY26: Rs 296.00 cr)
- H1FY27 EBITDA Margin (%): 22% (H1FY26: 25%)
- H1FY27 Depreciation: Rs 87.00 cr (H1FY26: Rs 84.00 cr)
- H1FY27 Finance Cost: Rs 18.00 cr (H1FY26: Rs 45.00 cr)
- H1FY27 PBT: Rs 220.00 cr (H1FY26: Rs 177.00 cr)
- H1FY27 PAT: Rs 164.00 cr (H1FY26: Rs 131* crore)
- H1FY27 PAT Margin (%): 11% (H1FY26: 11%)
- H1FY27 EPS (Rs): 37.9 (H1FY26: 30.3)
*The Income Statement table notes that, as the company shifted to a new tax rate of 25.17%, deferred tax liability reduced by Rs 81.00 cr, resulting in PAT of Rs 212.00 cr for H1FY26. If the reduction of deferred tax liability is excluded, PAT would be Rs 131.00 cr for H1FY26. The table itself uses "131*" for comparison.
In Q2FY27, Total Revenue and PAT increased versus Q2FY26, while the reported Gross Margin (%) and EBITDA Margin (%) were lower year-on-year. Finance Cost in the quarter was lower than in the corresponding quarter of the previous year, and EPS (Rs) was higher. On a half-year basis, H1FY27 shows higher Total Revenue, EBITDA, PBT and PAT compared with H1FY26, with Gross Margin (%) and EBITDA Margin (%) lower than the prior period, and EPS (Rs) higher.
Track Epigral Ltd
Cruxal reads every Epigral Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Get every filing that moves a stock
One email before the open, with the day's filings that actually shifted a price — the number, the source document and what the market did with it. Free, and you can unsubscribe from any issue.
Cruxal publishes market coverage for information only. Nothing here is investment advice.
